NCT06322095View on ClinicalTrials.gov

A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 22, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Patients With Advanced Solid TumorAdvanced Solid Tumor With Oncogenic Driver Mutations
Interventions
DRUG

PD-1

Previous PD-1

DRUG

MET inhibitor

Previous MET inhibitor

DRUG

ALK inhibitor

Previous ALK inhibitor

DRUG

BRAF Inhibito

Previous BRAF inhibitor

DRUG

EGFR Monoclonal antibody

Previous EGFR Monoclonal antibody

DRUG

GH21

Oral, 15mg BIW or 6mg QD

DRUG

MEK Inhibitor

Previous MEK Inhibitor

Trial Locations (2)

100029

RECRUITING

Cancer Hospital Chinese Academy of Medical Science, Beijing

210008

NOT_YET_RECRUITING

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
lead

Suzhou Genhouse Bio Co., Ltd.

OTHER